Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
第一三共和阿斯利康的HR+、HER2低乳腺癌顯示出統計學上顯著且具有臨床意義的改善：Destiny-breast06試驗結果
- Daiichi Sankyo and AstraZeneca's ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression
- Plans for global regulatory submissions are underway
- 第一三共和阿斯利康的ENHERTU還顯示，HER2超低表達患者的無進展存活率改善具有臨床意義
- 全球監管申報計劃正在進行中
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。